A5060088750- Renal Transplantation Outcomes and Treatments
- Diabetes Treatment and Management
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Transplantation: Methods and Outcomes
- Organ Transplantation Techniques and Outcomes
- Viral Infections and Immunology Research
- Adenosine and Purinergic Signaling
- Antiplatelet Therapy and Cardiovascular Diseases
- Atrial Fibrillation Management and Outcomes
- Peptidase Inhibition and Analysis
- Pregnancy and Medication Impact
- Pancreatic function and diabetes
- Bipolar Disorder and Treatment
- Hemoglobinopathies and Related Disorders
- Blood Coagulation and Thrombosis Mechanisms
- Metabolism, Diabetes, and Cancer
- Heart Failure Treatment and Management
- Cardiac Structural Anomalies and Repair
- Neuroendocrine Tumor Research Advances
- Mechanical Circulatory Support Devices
- Inflammatory Myopathies and Dermatomyositis
- Iron Metabolism and Disorders
- Pharmacological Effects and Toxicity Studies
- Kawasaki Disease and Coronary Complications
- Eosinophilic Disorders and Syndromes
Seattle Children's Hospital
2017-2024
University of Washington
2019-2024
University Health System
2017
Austin College
2017
The University of Texas at Austin
2017
The University of Texas Health Science Center at San Antonio
2017
Abstract Background: Direct oral anticoagulants have the potential to improve care in children requiring chronic anticoagulation. Edoxaban has favourable pharmacokinetics that could benefit younger patients but data on long-term safety and efficacy for specific paediatric indications are lacking. Study Aims: We present a single-centre experience using edoxaban who require anticoagulation large coronary artery aneurysms secondary Kawasaki disease. Methods: Weight-based dosing of once-daily...
Post-transplant diabetes mellitus (PTDM) can lead to significant morbidity and cardiovascular death with a functioning graft. A paucity of literature exists regarding glycemic control in solid-organ transplant (SOT) recipients, including pharmacist management PTDM. This study aimed assess the impact interventions on pharmacist-run PTDM clinic.This was single-center, prospective, observational 24 adult SOT recipients enrolled pilot pharmacist-managed clinic from 1 January 30 June...
Abstract Literature is limited comparing induction immunosuppression in pediatric liver transplant (LTx) recipients. This a single‐center, retrospective cohort study of primary transplants at our center between 2005 and 2016 who received either basiliximab (BSX) or rabbit anti‐thymocyte globulin (rATG) induction. Maintenance consisted tacrolimus ± corticosteroid taper. Exclusions included receipt an ABO‐incompatible graft, retransplantation, multi‐organ transplantation. Primary outcomes were...
Abstract Introduction The prevalence of iron deficiency and anemia in the setting modern‐day maintenance immunosuppression pediatric heart transplant (HTx) recipients is unclear. primary aim was to determine (serum ferritin < 30 ng/mL ± transferrin saturation 20%) per World Health Organization diagnostic criteria associated risk factors. Methods Single‐center, cross‐sectional analysis 200 consecutive HTx (<21 years old) from 2005 2021. Data were collected at 1‐year post‐HTx time annual...
Introduction: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are proven to reduce risk of cardiovascular death and hospitalization for heart failure (HF) in adults with reduced or preserved ejection fraction (EF). There limited data on SGLT2i use pediatric HF. Hypothesis: Addition standard HF medical therapy children left ventricular (LV) systolic dysfunction is associated improved clinical outcomes. Methods: Single-center observational analysis 65 patients (≤ 21 years old) LV (n=44...
Abstract CNIs are the mainstay of immunosuppressive therapy after pediatric HTx. While regular laboratory surveillance is performed to ensure blood levels within targeted range, risk acute rejection associated with subtherapeutic CNI has never been quantified. This a retrospective single‐center review 8413 trough in 138 HTx recipients who survived >1 year Subtherapeutic were defined as <50% lower limit target range. The acute, late (>12 months post‐transplant) following recipients'...
Literature is limited comparing adverse effects (AEs) of the proliferation signal inhibitors (PSIs) sirolimus (SRL) and everolimus (EVL) in pediatric heart transplant (HTx) recipients.Single-center, observational cohort analysis assessing first use SRL or EVL HTx recipients <21 years age with up to 2 follow-up between 2009 2020.Eighty-seven patients were included, 52 (59.8%) receiving 35 (40.2%) SRL. Tacrolimus PSI was most common regimen. Intergroup comparison revealed lower baseline...
Pharmacokinetics of mycophenolic acid (MPA) display substantial interpatient variability, with up to 10-fold difference exposure in individual patients under a fixed-dose regimen. MPA trough level (C0) monitoring is common clinical practice but has not proven sufficiently informative predicting or patient outcomes, especially children. No limited sampling strategies (LSSs) have been generated from pediatric heart transplant (HTx) recipients estimate AUC.Single-center, observational analysis...